Stovek

Catalog Veterinary products

Ceftidgect LA-TRV

download the instructions

Ceftidgect LA-TRV

Description:

Ceftigekt LA-TRV is an antibacterial veterinary product.

Dosage form: suspension for intramuscular and subcutaneous injection.

Composition:

1 ml of the veterinary product contains 100 mg of ceftiofur (as crystalline free ceftiofuric acid), excipients (methylparaben, propylparaben, butylhydroxytoluene, vegetable oil) and base (medium chain triglycerides).

Indications for use:

The veterinary product is used for treatment of cattle and small ruminants, poultry and pigs with infectious diseases of bacterial etiology of respiratory system, gastrointestinal tract and urogenital system; in sepsis, peritonitis, pyelonephritis, polyarthritis, polyserositis, wounds, postnatal infections, mastitis, necrobacillosis and other caused by microorganisms sensitive to ceftiofur.

Method of administration and dosage:

Cattle and small ruminants

The product is administered once, subcutaneously in dose of 1 ml per 15 kg of animal body weight (equivalent to 6.6 mg ceftiofur per 1 kg). It is recommended to administer not more than 20 ml at a single injection site

Poultry

the preparation is administered singly, intramuscularly in dose 0.05-0.2 ml per 10 kg body weight (1-4 mg ceftiofur per 1 kg body weight)

Pigs

the preparation is administered once intramuscularly in dose of 1 ml per 20 kg of animal body weight (equivalent of 5 mg ceftiofur per 1 kg). It is recommended to administer not more than 4 ml at a single injection site.

Pharmaceutical properties

Ceftiofur is a third-generation, broad-spectrum cephalosporin antibiotic with bactericidal action against Gram-negative (Escherichia coli, Klebsiella spp., Pasteurella spp., Haemophilus spp., Actinobacillus pleuropneumoniae., Bacteroides spp., Citrobacter spp., Enterobacter spp., Salmonella spp.,) and Gram-positive bacteria (Bacillus spp., Streptococcus spp., Staphylococcus spp., Actinomyces pyogenes), including lactamase-producing strains as well as some strains of anaerobes (Proteus spp., Fusobacterium necrophorum).

The veterinary product inhibits the enzyme transpeptidase, disrupting the synthesis of peptidoglucan, a mucopeptide of the cell membrane, leading to disruption of its growth and lysis of bacteria.

After parenteral administration in therapeutic dose maximum concentration of active substance is achieved in blood plasma of cattle after 12 hours, and in pigs - after 22 hours and maintained at therapeutic level for at least 7 days.

In the body ceftiofur is rapidly metabolised to form desfuroylceftiofur, which has activity equivalent to ceftiofur against bacteria. This active metabolite binds reversibly to plasma proteins and accumulates at the site of infection, and its activity is not reduced in the presence of necrotic tissue. The elimination of the veterinary product from animals occurs mainly with urine (about 70%) and faeces (12-15%). In case of liver and kidney dysfunction, the elimination period may be prolonged.